Nipro’s Serge Kemps, Chief Executive Officer, explains how the COVID-19 pandemic and its after-effects led the Japanese-headquartered medtech firm to diversify its offering beyond its traditional area of focus, renal care, and establish a footprint in interventional cardiology.
Here is the interview
Kemps also outlines some of the challenges of moving towards a truly value-based healthcare system in Belgium and Europe, and the role he sees for companies like Nipro in helping build it.
Want to experience working at Nipro?
Explore our current job openings here!